Back to News
Market Impact: 0.25
WuXi XDC Grants Ona Therapeutics Global Rights To WuXiTecan-2 Payload-Linker Platform
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual PropertyTechnology & Innovation
WuXi XDC Cayman entered an out-licensing agreement granting Ona Therapeutics exclusive worldwide rights to its proprietary WuXiTecan-2 antibody-drug conjugate payload-linker technology. The agreement supports commercialization of WuXi XDC's bioconjugation intellectual property, although the provided article excerpt does not disclose financial terms, development milestones, or royalty details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Ryanair CEO warns fares could rise by up to 20% in 2027 as fuel bill jumps by $2.2 billion
- The AI trade has broken down. How we got here and what investors should expect next
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- NUBURU Completes Tekne Acquisition, Adding a $93 Million Defense & Dual-Use Program Portfolio and Advancing Expansion Across NATO and Allied Markets
- BTIG cuts Acumen Pharmaceuticals stock price target to $1 on trial results
- Aehr Test Systems earnings on deck amid AI chip boom